bastijn
InnoSer expands its preclinical neuroscience expertise with the acquisition of Sylics
| General
This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis as well as key rare ...
Stay up-to-date
Sign up for our newsletter and stay up-to-date with the latest news and publications